|
|
Line 1: |
Line 1: |
− | {{Bio
| + | #REDIRECT [[AltUser:Guglielmo_Roma]] |
− | |Name=Guglielmo
| + | |
− | |Surnames=Roma
| + | |
− | |Photo=Guglielmo Roma.jpg
| + | |
− | |Position=Former Unit Leader
| + | |
− | |Email_address=guglielmo.roma@crg.es
| + | |
− | |Phone=+34 93 316 01 81
| + | |
− | |HomePage=http://es.linkedin.com/in/guglielmoroma
| + | |
− | }}
| + | |
− | Since 2002 I have been working as bioinformatician in both Academic ([http://www.ceinge.unina.it/ CEINGE], [http://www.tigem.it/ TIGEM], [http://www.crg.cat/ CRG]) and Pharmaceutical environments ([http://www.merckserono.com/en/index.html MerckSerono International], currently Novartis). I obtained a master degree in Biology (University of Naples 1996-2001), a post-lauream Master in Bioinformatics (University of Benevento, 2002-2003) and a post-lauream Specialization in Clinical Biochemistry (Second University of Naples, 2001-2006), and I am particularly interested into -omics sciences. As bioinformatician, I have contributed to several research projects (e.g. the discovery of novel transcripts expressed in ES cells [http://www.ncbi.nlm.nih.gov/pubmed/17540781], the development of biological resources and databases [http://www.ncbi.nlm.nih.gov/pubmed/19906694][http://www.ncbi.nlm.nih.gov/pubmed/17942430], the identification of disease genes using comparative genomics approaches [http://www.ncbi.nlm.nih.gov/pubmed/16174644] [http://sulfabase.tigem.it/], the discovery of gene regulatory networks, among others). In MerckSerono, I was involved in the identification of clinical biomarkers (Phase Ia and Ib) through genomics data analysis approaches, and provided ad-hoc bioinformatics support to internal projects.
| + | |
− | | + | |
− | In September 2009, I had the pleasure to start-up the Bioinformatics Core Facility at the CRG with the main goal to provide scientists, at CRG/PRBB and external institutions, with computational and data analysis expertise.
| + | |
− | | + | |
− | Since August 2011, I am Senior Investigator, Bioinformatics Group Leader, at the [http://www.novartis.com/ Novartis Pharma AG].
| + | |